Global Axial Spondyloarthritis Treatment Market 2018-2022
About Axial Spondyloarthritis Treatment
Axial spondyloarthritis treatment market covers the drugs used for the treatment of inflammatory rheumatic disease, which predominantly affects the spine and sacroiliac joints.
Technavio’s analysts forecast the Global Axial Spondyloarthritis Treatment Market to grow at a CAGR of 7.37% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the axial spondyloarthritis treatment market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of axial spondyloarthritis across the globe.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report - Global Axial Spondyloarthritis Treatment Market 2018-2022
Technavio recognizes the following companies as the key players in the global axial spondyloarthritis treatment market: AbbVie, Amgen, Johnson & Johnson, Pfizer, and UCB.
Commenting on the report, an analyst from Technavio’s team said: “One trend affecting this market is the increase in the number of small molecules in the drug development pipeline. Small molecules are generally less expensive than biologics and they are expected to gain traction during the forecast period.”
According to the report, one driver influencing this market is the increase in the number of approved biosimilars that is widening the patient base. Considering the high cost of biologics, biosimilars appear as a cost-effective solution and the rise in the number of approved biosimilars will fuel the growth of the global axial spondyloarthritis market during the period of forecast.
Further, the report states that one challenge affecting this market is the high cost of biologics. Biologics are expensive due to some critical factors such as the high research and development costs and the lengthy testing and manufacturing process which is hindering the growth of the market.
Johnson & Johnson